Response to letter entitled: Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
1 University Hospital Cologne, Department I of Internal Medicine, Lung Cancer Group Cologne (LCGC), National Network Genomic Medicine (nNGM), Cologne, Germany. Electronic address: anna.kron@uk-koeln.de.
2 University Hospital Cologne, Department I of Internal Medicine, Lung Cancer Group Cologne (LCGC), National Network Genomic Medicine (nNGM), Cologne, Germany.